SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jung F, Koscielny J, Mrowietz C, et al. Einfluss der Molekülstruktur von Hydroxyethylstärke auf die Eliminationskinetik und die Fliessfähigkeit des Blutes bei Probanden. Arzneimittelforschung 1993; 43: 99105.
  • 2
    Lenz K, Schimetta W, Pölz W, et al. Intestinal elimination of hydroxyethyl starch? Intensive Care Med 2000; 26: 7339.
  • 3
    Sommermeyer K, Cech F, Schmidt M, Weidler B. Klinisch verwendete Hydroxyethylstärke: physikalisch-chemische Charakterisierung. Krankenhauspharmazie 1987; 8: 2718.
  • 4
    Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethylstarch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 2002; 95: 54451.
  • 5
    Jungheinrich C, Neff TA. Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet 2005; 44: 68199.
  • 6
    Hulse JD, Jacobi A. Hetastarch: an overview of the colloid and its metabolism. Drug Intell Clin Pharm 1983; 17: 33441.
  • 7
    Leuschner J, Opitz J, Winkler A, Scharpf R, Bepperling F. Tissue storage of 14C-labeled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration in rats. Drugs R D 2003; 4: 3318.
  • 8
    Wilkes NJ, Woolf RL, Powanda MC, et al. Hydroxyethyl starch in balanced electrolyte solutions (Hextend): pharmacokinetic and pharmacodynamic profiles in healthy volunteers. Anesth Analg 2002; 94: 53844.
  • 9
    Yacobi A, Stoll RG, Sum CY, et al. Pharmacokinetics of hydroxyethyl starch in normal subjects. J Clin Pharmacol 1982; 22: 20612.
  • 10
    Boon JC, Jesch F, Ring J, Messmer K. Intravascular persistence of hydroxyethyl starch in man. Eur Surg Res 1976; 8: 497503.
  • 11
    Mishler JM, Borberg H, Emerson PM, Gross R. Hydroxyethyl starch: an agent for hypovolemic shock. J Surg Res 1977; 23: 23945.
  • 12
    Weidler B, Von Bormann B, Sommermeyer K, et al. Pharmakokinetische Merkmale als Kriterien für den klinischen Einsatz von Hydroxyethylstärke. Arzneimittelforschung 1991; 41: 4948.
  • 13
    Köhler H, Zschiedrich H, Linfante A, et al. Die Elimination von Hydroxyäthylstärke 200/0.5, Dextran 40 und Oxypolygelatine. Klin Wochenschr 1982; 60: 293301.
  • 14
    Asskali F, Förster H.. Zur Kumulation unterschiedlich substituierter Hydroxyethylstärke (HES) nach repetitiver Infusion bei gesunden Versuchspersonen. Anaesthesiol Intensivmed Unfallmed Notfallmed Schmerzther 1999; 34: 53741.
  • 15
    Lehmann G, Asskali F, Förster H. Pharmacokinetics of hydroxyethyl starch (70/0.5) following repeated infusions. Transfus Med Hemother 2003; 30: 727.
  • 16
    Waitzinger J, Bepperling F, Pabst G, et al. Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES (130/0.4)] after single dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998; 16: 15160.
  • 17
    Waitzinger J, Bepperling F, Pabst G, Opitz J. Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 2003; 4: 14957.
  • 18
    Költringer P, Pfeiffer KP, Lind P, et al. Hämodilution mit mittelmolekularer Hydroxyäthylstäke – 6% HAES 200.000/0.60-0.66 – bei Patienten mit peripherer arterieller Verschlusskrankheit. Österreichische Krankenhauspharmazie 1989; 3: 712.
  • 19
    Treib J, Haass A, Pindur G, et al. Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Eur J Haematol 1996; 56: 16872.
  • 20
    Kroemer H, Haass A, Müller K, et al. Hemodilution therapy in ischaemic stroke; plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5. Eur J Clin Pharm 1987; 31: 70510.
  • 21
    Treib J, Haass A, Pindur G, et al. HES 200/0.5 is not HES 200/0.5: influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74: 14526.
  • 22
    Jungheinrich C, Sauermann W, Bepperling F, Vogt NH. Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs R D 2004; 5: 19.
  • 23
    Lang K, Boldt J, Suttner S, Haisch G. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg 2001; 93: 4059.
  • 24
    Standl T, Burmeister MA, Schroeder F, et al. Hydroxyethyl starch (HES) 130/0.4 provides larger and faster increases in tissue oxygen tension in comparison with prehemodilution values than HES 70/0.5 or HES 200/0.5 in volunteers undergoing acute normovolemic hemodilution. Anesth Analg 2003; 96: 93643.
  • 25
    Neff T, Fischler L, Mark M, Stocker R, Reinhart W. The influence of two different hydroxyethyl starch solutions (6% HES 130/0.4 and 200/0.5) on blood viscosity. Anesth Analg 2005; 100: 177380.
  • 26
    Köhler H, Kirch W, Klein H, Distler A. Die Volumenwirkung von 6% Hydroxyäthylstärke 450/0.7, 10% Dextran 40 und 3,5% isozyanatvernetzter Gelatine bei Patienten mit terminaler Niereninsuffizienz. Anaesthesist 1978; 27: 4216.
  • 27
    Metcalf W, Papadopoulos A, Tufaro R, Barth A. A clinical physiologic study of hydroxyethyl starch. Surg Gynecol Obstet 1970; 131: 25567.
  • 28
    Waitzinger J, Bepperling F, Pabst G, et al. Effect of a new HES specification (6% HES 130/0.4) on blood and plasma volume after bleeding in 12 healthy male volunteers. Clin Drug Invest 1999; 17: 11925.
  • 29
    Jacob M, Rehm M, Orth V, et al. Exakte Messung des Volumeneffektes von 6%iger Hydroxyethylstärke 130/0,4 (Voluven®) während präoperativer akuter normovolämer Hämodilution. Anaesthesist 2003; 52: 896904.
  • 30
    James MF, Latoo MY, Mythen MG, et al. Plasma volume changes associated with two hydroxyethyl starch colloids following acute hypovolaemia in volunteers. Anaesthesia 2004; 59: 73842.
  • 31
    Kasper SM, Strömich A, Kampe S, Radbruch L. Evaluation of a new hydroxyethyl starch solution (HES 130/0.4) in patients undergoing preoperative autologous blood donation. J Clin Anesth 2001; 13: 48690.
  • 32
    Boldt J, Lehmann A, Römpert R, Haisch G, Isgro F. Volume therapy with a new hydroxyethyl starch in cardiac surgical patients before cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000; 14: 2648.
  • 33
    Ickx BE, Bepperling F, Melot C, Schulman C, Van der Linden PJ. Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended acute normovolaemic haemodilution. Br J Anaesth 2003; 91: 196202.
  • 34
    Gallandat Huet RC, Siemons AW, Baus D, et al. A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anesth 2000; 47: 120715.
  • 35
    Langeron O, Doelberg M, Ang ET, et al. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001; 92: 85562.
  • 36
    Gandhi SD, Weiskopf RB, Jungheinrich C, et al. Volume replacement therapy during major orthopedic surgery using Voluven® (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology 2007; 106: 11207.
  • 37
    Boldt J, Haisch G, Suttner S, Kumle B, Schellhaass A. Effects of a modified, balanced hydroxyethyl starch preparation (Hextend®) on measures of coagulation. Br J Anaesth 2002; 89: 7228.
  • 38
    Haisch G, Boldt J, Krebs C, et al. The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES 130/0.4) on coagulation in patients undergoing major abdominal surgery. Anesth Analg 2001; 92: 56571.
  • 39
    Haisch G, Boldt J, Krebs C, et al. Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 2001; 15: 31621.
  • 40
    Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 1985; 25: 34954.
  • 41
    Treib J, Haass A, Pindur G, et al. All medium starches are not the same: influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation. Transfusion 1996; 36: 4505.
  • 42
    Van der Linden PJ, De Hert SG, Deraedt D, et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg 2005; 101: 62934.
  • 43
    Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. Hydroxyethyl starch 130/0.4 reduces blood loss: a pooled analysis of randomized clinical trials. Anesthesiology 2006; 105: A1020.
  • 44
    Cittanova ML, Leblanc I, Legendre C, et al. Effect of hydroxylethyl starch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 16202.
  • 45
    Deman A, Peeters P, Sennesael J. Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. Nephrol Dial Transplant 1999; 14: 151720.
  • 46
    Kumle B, Boldt J, Piper S, et al. The influence of different intravascular volume replacement regimens on renal function in the elderly. Anesth Anlag 1999; 89: 112430.
  • 47
    Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethyl starch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357: 91116.
  • 48
    Boldt J, Brenner T, Lang J, Kumle B, Isgro F. Kidney-specific proteins in elderly patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 2003; 97: 15829.
  • 49
    Winkelmayer WC, Glynn RJ, Levin R, Avorn J. Hydroxyethyl starch and change in renal function in patients undergoing coronary bypass graft surgery. Kidney Int 2003; 64: 10469.
  • 50
    Boldt J, Priebe HJ. Intravascular volume replacement with synthetic colloids: is there an influence on renal function? Anesth Analg 2003; 96: 37682.
  • 51
    Gosling P, Rittoo D, Manji M, Mahmood A, Vohra R. Hydroxyethyl starch as a risk factor for acute renal failure in severe sepsis. Lancet 2001; 358: 5813.
  • 52
    Dehne MG, Muhling J, Sablotzki A, et al. Hydroxyethyl starch (HES) does not directly affect renal function in patients with no prior renal impairment. J Clin Anesth 2001; 13: 10311.
  • 53
    Neff TA, Doelberg M, Jungheinrich C, et al. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 2003; 96: 14539.
  • 54
    Sakr Y, Payen D, Reinhart K, et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007; 98: 21624.
  • 55
    Godet G, Lehot JJ, Janvier G, et al. Does volume substitution with HES 130/0.4 affect renal safety in abdominal aortic surgery? Crit Care 2006; 10(Suppl. 1): 173.
  • 56
    Ellger B, Freyhoff J, Van Aken H, Booke M, Marcus MA. High-dose volume replacement using HES 130/0.4 during major surgery. Impact on coagulation and incidence of postoperative itching. Nederlands Tijdschrift voor Anesthesiologie 2006; 19: 638.
  • 57
    Kasper SM, Meinert P, Kampe S, et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 2003; 99: 427.
  • 58
    Lochbühler H, Galli C, Hagemann H. Hydroxyethyl starch HES 130/0.4 in paediatric surgery: results of an explorative, controlled, multicentre safety study. Crit Care 2003; 7(Suppl. 2): 107.
  • 59
    Sirtl C, Laubenthal H, Zumtobel V, Kraft D, Jurecka W. Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. Br J Anaesth 1999; 82: 51015.
  • 60
    Dieterich HJ, Nohé B, Deschner N. Modulation von Phagozytose und Endothelfunktion. Anaesthesiol Intensivmed Notfallmed Schmerzther 1998; 33: 2704.
  • 61
    Mills GH. Hydroxyethyl starch: does our choice of colloid prevent or add to renal impairment? (Editorial I). Br J Anaesth 2007; 98: 1579.
  • 62
    Moran M, Kapsner C. Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med 1987; 317: 1503.
  • 63
    Swedish Product Information For Voluven. Accessed at http://www.lakemedelsverket.se/upload/SPC_PIL/Pdf/humspc/Voluven%20solution%20for%20infusion.pdf (accessed 8 June 2007).